title: Mantle cell lymphoma of the iris.
authors.forename: Mario A
authors.initials: MA
authors.lastname: Economou
authors.forename: Eva Dafgård
authors.initials: ED
authors.lastname: Kopp
authors.forename: Charlotta
authors.initials: C
authors.lastname: All-Ericsson
authors.forename: Stefan
authors.initials: S
authors.lastname: Seregard
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D017809:Fatal Outcome; D006801:Humans; D015811:Iris Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D008297:Male; D009364:Neoplasm Recurrence, Local; D018918:Phacoemulsification; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab